IPP Bureau

Novo Nordisk’s Wegovy pill approved in US as first oral GLP-1 for weight management
Novo Nordisk’s Wegovy pill approved in US as first oral GLP-1 for weight management

By IPP Bureau - December 23, 2025

Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial

Bayer wins Japan nod for finerenone in broad heart failure population
Bayer wins Japan nod for finerenone in broad heart failure population

By IPP Bureau - December 23, 2025

Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients

China approves first-in-class TGCT drug, marking global first for pimicotinib
China approves first-in-class TGCT drug, marking global first for pimicotinib

By IPP Bureau - December 23, 2025

FDA grants breakthrough therapy designation to Enhertu for high-risk early breast cancer
FDA grants breakthrough therapy designation to Enhertu for high-risk early breast cancer

By IPP Bureau - December 23, 2025

This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care

SRM Global Hospitals performs Tamil Nadu’s first TactiFlex radiofrequency ablation to save 80-yr-old patient
SRM Global Hospitals performs Tamil Nadu’s first TactiFlex radiofrequency ablation to save 80-yr-old patient

By IPP Bureau - December 23, 2025

TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.

LATIFY Phase III trial of Ceralasertib fails to improve survival in advanced lung cancer
LATIFY Phase III trial of Ceralasertib fails to improve survival in advanced lung cancer

By IPP Bureau - December 23, 2025

The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy

FDA go-ahead to Roche’s one-minute follicular lymphoma therapy
FDA go-ahead to Roche’s one-minute follicular lymphoma therapy

By IPP Bureau - December 23, 2025

Full approval will depend on verification of clinical benefit in a confirmatory trial

Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug
Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug

By IPP Bureau - December 23, 2025

The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa

FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy

By IPP Bureau - December 23, 2025

The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity

Glenmark Pharmaceuticals USA launches Epinephrine Injection USP, multiple-dose vial
Glenmark Pharmaceuticals USA launches Epinephrine Injection USP, multiple-dose vial

By IPP Bureau - December 23, 2025

According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million

Biocon Biologics expands FKB deal to secure global rights for Adalimumab biosimilar
Biocon Biologics expands FKB deal to secure global rights for Adalimumab biosimilar

By IPP Bureau - December 23, 2025

Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized

Biocon inks out-licensing agreement with Ajanta to market Semaglutide in 26 countries
Biocon inks out-licensing agreement with Ajanta to market Semaglutide in 26 countries

By IPP Bureau - December 23, 2025

Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia

Cupid reduces promoter pledged stake to 20%
Cupid reduces promoter pledged stake to 20%

By IPP Bureau - December 23, 2025

This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence

TAKE Solutions plans AI-driven healthcare platform
TAKE Solutions plans AI-driven healthcare platform

By IPP Bureau - December 23, 2025

The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities

Zydus Partners with Bioeq for US commercialisation rights for Nufymco
Zydus Partners with Bioeq for US commercialisation rights for Nufymco

By IPP Bureau - December 23, 2025

NUFYMCO BLA has been approved by the USFDA

Latest Stories

Interviews

Packaging